Advertisement

Topics

Akebia Therapeutics, Inc.  Company Profile

14:51 EST 23rd January 2019 | BioPortfolio

Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor biology. For more information, please visit our website at www.akebia.com, which does not form a part of this release.


News Articles [681 Associated News Articles listed on BioPortfolio]

Akebia Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, tod...

Akebia, Keryx Bio announce successful completion of merger

Akebia Therapeutics and Keryx Biopharmaceuticals have completed the merger of their companies and are doing business under Ak -More- 

Akebia Therapeutics to Host Second Quarter 2018 Investor Update Call and Webcast

Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypox...

M&As this week: Cosmos Holdings, Akebia Therapeutics, Biogen

Cosmos Holdings has signed a share purchase agreement to acquire 100% interest in Cosmofarm Ltd (Cosmofarm) for an undisclosed sum. The...Read More... The post M&As this week: Cosmos Holdings, A...

Former Akebia and Merrimack Employees Convicted of Insider Trading

Schultz Chan, the former director of biostatistics at Cambridge-based Akebia Therapeutics and Songjiang Wang, a director of statistical programming at Merrimack Pharmaceuticals (MACK) were convicted o...

Akebia Therapeutics Is An Attractive Investment In 2018

Keryx Biopharmaceuticals Stockholders Approve Merger with Akebia Therapeutics

BOSTON, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today an...

Keryx Biopharmaceuticals And Akebia Therapeutics: Was The Reaction To The Merger Announcement Justified?

Drugs and Medications [27 Associated Drugs and Medications listed on BioPortfolio]

Kynamro [Kastle Therapeutics, LLC]

NA

Olopatadine hydrochloride [Somerset Therapeutics, LLC]

OLOPATADINE Hydrochloride Ophthalmic Solution USP, 0.1%Somerset Therapeutics, LLC

Oxygen [Breathe Easy Therapeutics, Inc]

NA

Diclofenac sodium delayed release [Cambridge Therapeutics Technologies, LLC]

Diclofenac Sodium

Olopatadine hydrochloride [A-S Medication Solutions]

OLOPATADINE Hydrochloride Ophthalmic Solution USP, 0.1%Somerset Therapeutics, LLC

PubMed Articles [473 Associated PubMed Articles listed on BioPortfolio]

Akebia saponin D reverses corticosterone hypersecretion in an Alzheimer's disease rat model.

Glucocorticoid hormones are implicated in the pathogenesis of Alzheimer's disease (AD) and other diseases including diabetes, hyperlipidemia, and osteoporosis. Akebia saponin D (ASD) possesses numerou...

The use of fast photochemical oxidation of proteins coupled with mass spectrometry in protein therapeutics discovery and development.

Structural analysis of protein therapeutics is a challenging task owing to complexities associated with large molecular size and 3D structures. Recent advances in fast photochemical oxidation of prote...

RNA-targeted therapeutics for lipid disorders.

To summarize recent developments in the field of RNA-directed therapeutics targeting lipid disorders that are not effectively managed.

A Review of Therapeutics in Clinical Development for Respiratory Syncytial Virus and Influenza in Children.

Respiratory syncytial virus (RSV) and influenza are important viral pathogens worldwide. Children, in particular, bear considerable burdens of morbidity and mortality associated with these viruses. Th...

Bacterial magnetosomes-based nanocarriers for co-delivery of cancer therapeutics in vitro.

In recent times, co-delivery of therapeutics has emerged as a promising strategy for treating dreadful diseases such as cancer.

Clinical Trials [169 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1292 Associated Companies listed on BioPortfolio]

Akebia Therapeutics, Inc. 

Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on delivering innovative therapies to patients with kidney diseas...

Akebia Therapeutics, Inc. and Keryx Biopharmaceuticals, Inc.

Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on delivering innovative therapies to patients with kidney disease th...

Akebia Therapeutics, Inc.

Akebia Therapeutics is a discovery and development company focused on anemia and vascular disorders. Akebia’s lead program, AKB-6548, an orally bioavailable HIF-prolyl hydrox...

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

More Information about "Akebia Therapeutics, Inc. " on BioPortfolio

We have published hundreds of Akebia Therapeutics, Inc.  news stories on BioPortfolio along with dozens of Akebia Therapeutics, Inc.  Clinical Trials and PubMed Articles about Akebia Therapeutics, Inc.  for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Akebia Therapeutics, Inc.  Companies in our database. You can also find out about relevant Akebia Therapeutics, Inc.  Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record